RSP Systems awarded €2.4m grant for non-invasive blood glucose measurement technology

Grant is part of the European Union's Horizon 2020 framework for research and innovation and funds will be used to take GlucoBeam through to market launch

RSP Systems, the Danish biotechnology company that specialises in non-invasive human diagnostics, has been awarded a €2.4m grant under the EU's Horizon 2020 framework for research and innovation.

The funds will be used to take GlucoBeam, the world's first accurate, non-invasive glucose monitor for diabetic patients, through to market launch. The grant follows a €4.6m Series A round in July that included leading business strategist Roland Berger together with existing investors.

GlucoBeam is based on RSP's proprietary and clinically validated technology, Critical Depth Raman Spectroscopy, which measure glucose in living tissue. Previous efforts to develop diagnostics for interstitial glucose in the skin were unsuccessful until RSP produced unequivocal evidence that by selecting a specific skin depth, results could be correlated with blood glucose levels.

Today, RSP is integrating the technology into a non-invasive consumer glucose monitor with an analytical quality on par with current standards for invasive continuous glucose monitoring technologies.

'This vital grant will help to overcome the biggest issue in glucose monitoring: compliance. For patients to finally be able to measure their glucose levels using the non-invasive GlucoBeam will be a real breath of fresh air,' said Dr Anders Weber, CEO of RSP Systems. 'With the completion of a commercial product aided by Horizon 2020, we can now identify the best path to the best partners to make GlucoBeam broadly available to patients in the European and later global markets.'